Literature DB >> 21284766

A novel oncoprotein Pirh2: rising from the shadow of MDM2.

Zhihao Wang1, Bo Yang, Lanlan Dong, Biwen Peng, Xiaohua He, Wanhong Liu.   

Abstract

Pirh2 (p53-induced RING-H2) is an E3 ubiquitin ligase that can target p53 for degradation and thereby repress a diverse group of biological activities regulated by p53. Notably, Pirh2, rather than MDM2, is the primary degrader of active p53 under conditions of DNA damage. Moreover, Pirh2 is highly expressed in multiple cancer cell lines regardless of p53 status. Recent research has shown that Pirh2 is involved in many signalling pathways related to the genesis and evolution of cancer. This review aims to summarize a comprehensive picture of the role of Pirh2 in cellular processes and its significance to tumorigenesis. Furthermore, this review focuses on its potential role as a cancer therapeutic target.
© 2011 Japanese Cancer Association.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21284766     DOI: 10.1111/j.1349-7006.2011.01899.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  8 in total

1.  The p73 tumor suppressor is targeted by Pirh2 RING finger E3 ubiquitin ligase for the proteasome-dependent degradation.

Authors:  Yong-Sam Jung; Yingjuan Qian; Xinbin Chen
Journal:  J Biol Chem       Date:  2011-08-18       Impact factor: 5.157

2.  Human Pirh2 is a novel inhibitor of prototype foamy virus replication.

Authors:  Lanlan Dong; Qingqing Cheng; Zhihao Wang; Peipei Yuan; Zhi Li; Yan Sun; Song Han; Jun Yin; Biwen Peng; Xiaohua He; Wanhong Liu
Journal:  Viruses       Date:  2015-04-02       Impact factor: 5.048

3.  The MDM2-p53 pathway revisited.

Authors:  Subhasree Nag; Jiangjiang Qin; Kalkunte S Srivenugopal; Minghai Wang; Ruiwen Zhang
Journal:  J Biomed Res       Date:  2013-06-06

4.  E3 ubiquitin ligase Pirh2 enhances tumorigenic properties of human non-small cell lung carcinoma cells.

Authors:  Alexandra Daks; Alexey Petukhov; Olga Fedorova; Oleg Shuvalov; Valeriy Merkulov; Elena Vasileva; Alexey Antonov; Nikolai A Barlev
Journal:  Genes Cancer       Date:  2016-11

Review 5.  Mechanism and Disease Association With a Ubiquitin Conjugating E2 Enzyme: UBE2L3.

Authors:  Xiaoxia Zhang; Chengdong Huo; Yating Liu; Ruiliang Su; Yang Zhao; Yumin Li
Journal:  Front Immunol       Date:  2022-02-21       Impact factor: 7.561

Review 6.  The emerging roles of E3 ubiquitin ligases in ovarian cancer chemoresistance.

Authors:  Yang Meng; Lei Qiu; Su Zhang; Junhong Han
Journal:  Cancer Drug Resist       Date:  2021-06-19

7.  WWP1 E3 ligase targets LATS1 for ubiquitin-mediated degradation in breast cancer cells.

Authors:  Benjamin Yeung; King-Ching Ho; Xiaolong Yang
Journal:  PLoS One       Date:  2013-04-03       Impact factor: 3.240

8.  Molecular Analysis of the HOXA2-Dependent Degradation of RCHY1.

Authors:  Laure Bridoux; Noémie Deneyer; Isabelle Bergiers; René Rezsohazy
Journal:  PLoS One       Date:  2015-10-23       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.